Home - News ( United States | United Kingdom | Italy | Germany ) - Football scores

Showing content from http://www.ncbi.nlm.nih.gov/pubmed/25925419 below:

US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines

Affiliations

• ¹ Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion (MSa, TDT, MW) and Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases (ERU, MSt), Centers for Disease Control and Prevention, Atlanta, GA; University of Hawaii Cancer Center, University of Hawaii, Honolulu, HI (MTG, BYH); Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, IA (CFL); Departments of Preventive Medicine (WC) and Pathology (WC, MSS), University of Southern California, Los Angeles, CA; Department of Epidemiology, School of Public Health, Louisiana State University Health Sciences Center, New Orleans, LA (ESP); Department of Pathology, Immunology, and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL (EJW); Michigan Department of Community Health, Lansing, MI (GC); Department of Epidemiology, College of Public Health, University of Kentucky, Lexington, KY (CH); Florida Department of Health, Tallahassee, FL (YH); Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, MD (SFA); Battelle Memorial Institute, Durham, NC (CWL); National Cancer Institute (SA). msaraiya@cdc.gov.
• ² Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion (MSa, TDT, MW) and Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases (ERU, MSt), Centers for Disease Control and Prevention, Atlanta, GA; University of Hawaii Cancer Center, University of Hawaii, Honolulu, HI (MTG, BYH); Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, IA (CFL); Departments of Preventive Medicine (WC) and Pathology (WC, MSS), University of Southern California, Los Angeles, CA; Department of Epidemiology, School of Public Health, Louisiana State University Health Sciences Center, New Orleans, LA (ESP); Department of Pathology, Immunology, and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL (EJW); Michigan Department of Community Health, Lansing, MI (GC); Department of Epidemiology, College of Public Health, University of Kentucky, Lexington, KY (CH); Florida Department of Health, Tallahassee, FL (YH); Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, MD (SFA); Battelle Memorial Institute, Durham, NC (CWL); National Cancer Institute (SA).

• PMID: 25925419
• PMCID: PMC4838063
• DOI: 10.1093/jnci/djv086

Item in Clipboard

Mona Saraiya et al. J Natl Cancer Inst. 2015.

• ¹ Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion (MSa, TDT, MW) and Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases (ERU, MSt), Centers for Disease Control and Prevention, Atlanta, GA; University of Hawaii Cancer Center, University of Hawaii, Honolulu, HI (MTG, BYH); Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, IA (CFL); Departments of Preventive Medicine (WC) and Pathology (WC, MSS), University of Southern California, Los Angeles, CA; Department of Epidemiology, School of Public Health, Louisiana State University Health Sciences Center, New Orleans, LA (ESP); Department of Pathology, Immunology, and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL (EJW); Michigan Department of Community Health, Lansing, MI (GC); Department of Epidemiology, College of Public Health, University of Kentucky, Lexington, KY (CH); Florida Department of Health, Tallahassee, FL (YH); Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, MD (SFA); Battelle Memorial Institute, Durham, NC (CWL); National Cancer Institute (SA). msaraiya@cdc.gov.
• ² Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion (MSa, TDT, MW) and Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases (ERU, MSt), Centers for Disease Control and Prevention, Atlanta, GA; University of Hawaii Cancer Center, University of Hawaii, Honolulu, HI (MTG, BYH); Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, IA (CFL); Departments of Preventive Medicine (WC) and Pathology (WC, MSS), University of Southern California, Los Angeles, CA; Department of Epidemiology, School of Public Health, Louisiana State University Health Sciences Center, New Orleans, LA (ESP); Department of Pathology, Immunology, and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL (EJW); Michigan Department of Community Health, Lansing, MI (GC); Department of Epidemiology, College of Public Health, University of Kentucky, Lexington, KY (CH); Florida Department of Health, Tallahassee, FL (YH); Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, MD (SFA); Battelle Memorial Institute, Durham, NC (CWL); National Cancer Institute (SA).

• PMID: 25925419
• PMCID: PMC4838063
• DOI: 10.1093/jnci/djv086

Item in Clipboard

Background: This study sought to determine the prevaccine type-specific prevalence of human papillomavirus (HPV)-associated cancers in the United States to evaluate the potential impact of the HPV types in the current and newly approved 9-valent HPV vaccines.

Methods: The Centers for Disease Control and Prevention partnered with seven US population-based cancer registries to obtain archival tissue for cancers diagnosed from 1993 to 2005. HPV testing was performed on 2670 case patients that were fairly representative of all participating cancer registry cases by age and sex. Demographic and clinical data were evaluated by anatomic site and HPV status. Current US cancer registry data and the detection of HPV types were used to estimate the number of cancers potentially preventable through vaccination.

Results: HPV DNA was detected in 90.6% of cervical, 91.1% of anal, 75.0% of vaginal, 70.1% of oropharyngeal, 68.8% of vulvar, 63.3% of penile, 32.0% of oral cavity, and 20.9% of laryngeal cancers, as well as in 98.8% of cervical cancer in situ (CCIS). A vaccine targeting HPV 16/18 potentially prevents the majority of invasive cervical (66.2%), anal (79.4%), oropharyngeal (60.2%), and vaginal (55.1%) cancers, as well as many penile (47.9%), vulvar (48.6%) cancers: 24 858 cases annually. The 9-valent vaccine also targeting HPV 31/33/45/52/58 may prevent an additional 4.2% to 18.3% of cancers: 3944 cases annually. For most cancers, younger age at diagnosis was associated with higher HPV 16/18 prevalence. With the exception of oropharyngeal cancers and CCIS, HPV 16/18 prevalence was similar across racial/ethnic groups.

Conclusions: In the United States, current vaccines will reduce most HPV-associated cancers; a smaller additional reduction would be contributed by the new 9-valent vaccine.

Published by Oxford University Press 2015. This work is written by (a) US Government employee(s) and is in the public domain in the US.

PubMed Disclaimer

Flow chart of selected cases…

Flow chart of selected cases from all cancer tissues, Centers for Disease Control…

Flow chart of selected cases from all cancer tissues, Centers for Disease Control and Prevention Cancer Registry Sentinel Surveillance System for human papillomavirus (HPV) typing of cancers. All samples were tested by Linear Array HPV genotyping test (LA), but if the results were inadequate or negative INNO-LiPA HPV genotyping (LiPA) was performed. If LiPA detected HPV, then the HPV results were based on the LiPA test.

Human papillomavirus (HPV) detection by…

Human papillomavirus (HPV) detection by cancer site. The percent HPV-positive cancers was determined…

Human papillomavirus (HPV) detection by cancer site. The percent HPV-positive cancers was determined using all cancers for that anatomic site as denominator. Ninety-five percent Wilson confidence limits around the prevalence estimates are presented. These percentages reflect the HPV DNA that was detected. Finding HPV in a cancer tissue does not necessarily indicate a causal relationship. International Agency for Research on Cancer defined some cancers to have strong evidence for causal etiology such as cervical, vaginal, vulvar, anal, penile, and oropharyngeal cancers. Oral cavity and laryngeal cancers are considered to have less evidence for causal etiology (larynx) and/or inconsistent correlation with HPV DNA detection and percent causal (oral cavity and larynx). Cancer sites were determined using the following ICD-O-3 morphology codes: C53 (cervix), C51 (vulva), C52 (vagina), C21 (anus), C60 (penis), and C01.9, C02.4, C02.8, C05.1, C05.2, C05.9, C09.0, C09.1, C09.8, C09.9, C10.0, C10.2, C10.8, C10.9, C14.0, C14.2, and C14.8 (oropharynx), C02.0, C02.1, C02.2, C02.3 C02.9, C03.0, C03.1, C03.9, C04.0, C04.1, C04.8, C04.9, C05.0, C06.0, C06.1, C06.2, C06.8, C06.9 (oral tongue and oral cavity), C32.0, C32.1, C32.2, C32.3, C32.8, C32.9 (larynx). ICD-O-3 morphology codes: 9590–9729, 9827 (lymphoma), 8800–8991 (sarcoma), and 8720–8790 (melanoma) were not included.

The seven most common oncogenic…

The seven most common oncogenic human papillomavirus (HPV) genotypes detected in select anogenital…

The seven most common oncogenic human papillomavirus (HPV) genotypes detected in select anogenital and head and neck cancers. A) Anogenital cancers incude cervical, vaginal, vulvar, anal, and penile cancers. B) Head and neck cancers include oropharyngeal, laryngeal, and oral cavity cancers. Number of types may add up to more than seven in instances where we found ties in the percentages.

The seven most common oncogenic…

The seven most common oncogenic human papillomavirus (HPV) genotypes detected in select anogenital…

The seven most common oncogenic human papillomavirus (HPV) genotypes detected in select anogenital and head and neck cancers. A) Anogenital cancers incude cervical, vaginal, vulvar, anal, and penile cancers. B) Head and neck cancers include oropharyngeal, laryngeal, and oral cavity cancers. Number of types may add up to more than seven in instances where we found ties in the percentages.

Population attribution of human papillomavirus…

Population attribution of human papillomavirus (HPV) in select anogenital and head and neck…

Population attribution of human papillomavirus (HPV) in select anogenital and head and neck cancers. A) Anogenital cancers include cervical, vaginal, vulvar, anal, and penile cancers. It should be noted that the International Agency for Research on Cancer (IARC) has defined some cancers to have strong evidence for a causal association of HPV 16 and 18 with cervical, vaginal, vulvar, anal, and penile. Percent multiple infections ranged by type of anogenital cancer: cervical 8.2%; in situ cervical 21.4%; vulvar 6.3%, in situ vulvar 7.4%, vaginal 15%, anal 11.0%, penile 11.4%. Ninety-five percent Wilson confidence limits around the prevalence estimates are presented. B) Select head and neck cancers include oropharyngeal (OP), laryngeal, and oral cavity (OC) cancers. According to IARC, there is strong evidence for a causal role of HPV 16 and 18 in oropharyngeal cancer. The oral cavity is considered to have evidence for a causal association with HPV, but some of the HPV DNA detected in tissues may not represent the true causal agent. Laryngeal cancer has limited evidence for a causal etiology with HPV; and the correlation of HPV DNA detected does not reflect the percentage that is causal. C) Percent multiple infections were similar across cancer types for OP, OC, and laryngeal cancers (4.1%). Ninety-five percent Wilson confidence limits around the prevalence estimates are presented.

Population attribution of human papillomavirus…

Population attribution of human papillomavirus (HPV) in select anogenital and head and neck…

Population attribution of human papillomavirus (HPV) in select anogenital and head and neck cancers. A) Anogenital cancers include cervical, vaginal, vulvar, anal, and penile cancers. It should be noted that the International Agency for Research on Cancer (IARC) has defined some cancers to have strong evidence for a causal association of HPV 16 and 18 with cervical, vaginal, vulvar, anal, and penile. Percent multiple infections ranged by type of anogenital cancer: cervical 8.2%; in situ cervical 21.4%; vulvar 6.3%, in situ vulvar 7.4%, vaginal 15%, anal 11.0%, penile 11.4%. Ninety-five percent Wilson confidence limits around the prevalence estimates are presented. B) Select head and neck cancers include oropharyngeal (OP), laryngeal, and oral cavity (OC) cancers. According to IARC, there is strong evidence for a causal role of HPV 16 and 18 in oropharyngeal cancer. The oral cavity is considered to have evidence for a causal association with HPV, but some of the HPV DNA detected in tissues may not represent the true causal agent. Laryngeal cancer has limited evidence for a causal etiology with HPV; and the correlation of HPV DNA detected does not reflect the percentage that is causal. C) Percent multiple infections were similar across cancer types for OP, OC, and laryngeal cancers (4.1%). Ninety-five percent Wilson confidence limits around the prevalence estimates are presented.

• Prevention of Human Papillomavirus Infection. Beyond Cervical Cancer: A Brief Review.

  Medeiros R, Vaz S, Rebelo T, Figueiredo-Dias M. Medeiros R, et al. Acta Med Port. 2020 Mar 2;33(3):198-201. doi: 10.20344/amp.12259. Epub 2020 Mar 2. Acta Med Port. 2020. PMID: 32130098 Review.

• Potential impact of a nonavalent HPV vaccine on the occurrence of HPV-related diseases in France.

  Riethmuller D, Jacquard AC, Lacau St Guily J, Aubin F, Carcopino X, Pradat P, Dahlab A, Prétet JL. Riethmuller D, et al. BMC Public Health. 2015 May 2;15:453. doi: 10.1186/s12889-015-1779-1. BMC Public Health. 2015. PMID: 25934423 Free PMC article.

• Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels.

  Jemal A, Simard EP, Dorell C, Noone AM, Markowitz LE, Kohler B, Eheman C, Saraiya M, Bandi P, Saslow D, Cronin KA, Watson M, Schiffman M, Henley SJ, Schymura MJ, Anderson RN, Yankey D, Edwards BK. Jemal A, et al. J Natl Cancer Inst. 2013 Feb 6;105(3):175-201. doi: 10.1093/jnci/djs491. Epub 2013 Jan 7. J Natl Cancer Inst. 2013. PMID: 23297039 Free PMC article.

• Cancers attributable to human papillomavirus infection.

  Grulich AE, Jin F, Conway EL, Stein AN, Hocking J. Grulich AE, et al. Sex Health. 2010 Sep;7(3):244-52. doi: 10.1071/SH10020. Sex Health. 2010. PMID: 20719211

• 9-Valent HPV vaccine for cancers, pre-cancers and genital warts related to HPV.

  Pitisuttithum P, Velicer C, Luxembourg A. Pitisuttithum P, et al. Expert Rev Vaccines. 2015;14(11):1405-19. doi: 10.1586/14760584.2015.1089174. Epub 2015 Sep 14. Expert Rev Vaccines. 2015. PMID: 26366475 Review.

• Incidence Trends and Burden of Human Papillomavirus-Associated Cancers Among Women in the United States, 2001-2017.

  Deshmukh AA, Suk R, Shiels MS, Damgacioglu H, Lin YY, Stier EA, Nyitray AG, Chiao EY, Nemutlu GS, Chhatwal J, Schmeler K, Sigel K, Sonawane K. Deshmukh AA, et al. J Natl Cancer Inst. 2021 Jun 1;113(6):792-796. doi: 10.1093/jnci/djaa128. J Natl Cancer Inst. 2021. PMID: 32833021 Free PMC article.

• Circulating HPV DNA in the Management of Oropharyngeal and Cervical Cancers: Current Knowledge and Future Perspectives.

  Krasniqi E, Barba M, Venuti A, Pizzuti L, Cappuzzo F, Landi L, Carpano S, Marchetti P, Villa A, Vizza E, Giuliano G, Mazzotta M, Marinelli D, Gnignera S, Vincenzoni C, Stranges V, Sergi D, Giordano A, Tomao F, Maugeri-Saccà M, Sanguineti G, Di Lisa FS, Tomao S, Ciliberto G, Vici P. Krasniqi E, et al. J Clin Med. 2021 Apr 6;10(7):1525. doi: 10.3390/jcm10071525. J Clin Med. 2021. PMID: 33917435 Free PMC article. Review.

• Update on the new 9-valent vaccine for human papillomavirus prevention.

  Yang DY, Bracken K. Yang DY, et al. Can Fam Physician. 2016 May;62(5):399-402. Epub 2016 May 12. Can Fam Physician. 2016. PMID: 27255620 Free PMC article. Review.

• Human papillomavirus types in cervical high-grade lesions or cancer among Nordic women-Potential for prevention.

  Dovey de la Cour C, Guleria S, Nygård M, Trygvadóttir L, Sigurdsson K, Liaw KL, Hortlund M, Lagheden C, Hansen BT, Munk C, Dillner J, Kjaer SK. Dovey de la Cour C, et al. Cancer Med. 2019 Feb;8(2):839-849. doi: 10.1002/cam4.1961. Epub 2019 Jan 11. Cancer Med. 2019. PMID: 30632704 Free PMC article.

• Multiple primary malignancies in patients with anal squamous cell carcinoma.

  Li D, Yegya-Raman N, Kim S, Ganesan S, Sayan M, August D, Spencer K, Hathout L, Maloney-Patel N, Malhotra U, Yue NJ, Jabbour SK. Li D, et al. J Gastrointest Oncol. 2018 Oct;9(5):853-857. doi: 10.21037/jgo.2018.06.07. J Gastrointest Oncol. 2018. PMID: 30505585 Free PMC article.

1. 1. Zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002;2(5):342–350. - PubMed
2. 1. Forman D, de Martel C, Lacey CJ, et al. Global burden of human papillomavirus and related diseases. Vaccine. 2012;30(Suppl 5):F12–F23. - PubMed
3. 1. International Agency for Research on Cancer IARC. Monographs on the evaluation of carcinogenic risks to humans: biologic agents. Human papillomaviruses. Vol. 100B. Lyon, France: IARC; 2012. http://monographs.iarc.fr/ENG/Monographs/vol100B/mono100B-11.pdf
4. 1. Bouvard V, Baan R, Straif K, et al. A review of human carcinogens-Part B: biological agents. The Lancet Oncol. 2009; 10(4):321–322. - PubMed
5. 1. Doorbar J, Quint W, Banks L, et al. The biology and life-cycle of human papillomaviruses. Vaccine. 2012;30(Suppl 5):F55–F70. - PubMed

RetroSearch is an open source project built by @garambo | Open a GitHub Issue

Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo

HTML: 3.2 | Encoding: UTF-8 | Version: 0.7.3